Roberto Angioli

Roberto Angioli

Auto-generated profile, based on publicly available information

Roberto Angioli

Department of Obstetrics and Gynaecology, Campus Bio-Medico, University of Rome, Rome, Italy

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 November 2008 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
PPPierluigi Benedetti Panici
Pierluigi Benedetti Panici
SBStefano Basile
Stefano Basile
FMFrancesco Maneschi
Francesco Maneschi
ALAndrea Alberto Lissoni
Andrea Alberto Lissoni
MSMauro Signorelli
Mauro Signorelli
CMCostantino Mangioni
Costantino Mangioni
Pelvic lymph nodes are the most common site of extrauterine tumor spread in early-stage endometrial cancer, but the clinical impact of lymphadenectomy has not been addressed in randomized studies. We conducted a randomized clinical trial to determine whether the addition of pelvic systematic lymphadenectomy to standard hysterectomy with bilateral salpingo-oophorectomy improves overall and disease-free survival. From October 1, 1996, through March 31, 2006, 514 eligible patients with preoperative International Federation of Gynecology and Obstetrics stage I endometrial carcinoma were randomly assigned to undergo pelvic systematic lymphadenectomy (n = 264) or no lymphadenectomy (n = 250). Patients’ clinical data, pathological tumor characteristics, and operative and early postoperative data were recorded at discharge from hospital. Late postoperative complications, adjuvant therapy, and follow-up data were collected 6 months after surgery. Survival was analyzed by use of the log-rank test and a Cox multivariable regression analysis. All statistical tests were two-sided. The median number of lymph nodes removed was 30 (interquartile range = 22–42) in the pelvic systematic lymphadenectomy arm and 0 (interquartile range = 0–0) in the no-lymphadenectomy arm ( P < .001). Both early and late postoperative complications occurred statistically significantly more frequently in patients who had received pelvic systematic lymphadenectomy (81 patients in the lymphadenectomy arm and 34 patients in the no-lymphadenectomy arm, P = .001). Pelvic systematic lymphadenectomy improved surgical staging as statistically significantly more patients with lymph node metastases were found in the lymphadenectomy arm than in the no-lymphadenectomy arm (13.3% vs 3.2%, difference = 10.1%, 95% confidence interval [CI] = 5.3% to 14.9%, P < .001). At a median follow-up of 49 months, 78 events (ie, recurrence or death) had been observed and 53 patients had died. The unadjusted risks for first event and death were similar between the two arms (hazard ratio [HR] for first event = 1.10, 95% CI = 0.70 to 1.71, P = .68, and HR for death = 1.20, 95% CI = 0.70 to 2.07, P = .50). The 5-year disease-free and overall survival rates in an intention-to-treat analysis were similar between arms (81.0% and 85.9% in the lymphadenectomy arm and 81.7% and 90.0% in the no-lymphadenectomy arm, respectively). Although systematic pelvic lymphadenectomy statistically significantly improved surgical staging, it did not improve disease-free or overall survival.

20 April 2005 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
PPPierluigi Benedetti Panici
Pierluigi Benedetti Panici
AMAngelo Maggioni
Angelo Maggioni
NHNeville Hacker
Neville Hacker
FLFabio Landoni
Fabio Landoni
SASven Ackermann
Sven Ackermann
CMCostantino Mangioni
Costantino Mangioni
Background: The role of systematic aortic and pelvic lymphadenectomy in patients with optimally debulked advanced ovarian cancer is unclear and has not been addressed by randomized studies. We conducted a randomized clinical trial to determine whether systematic aortic and pelvic lymphadenectomy improves progression-free and overall survival compared with resection of bulky nodes only. Methods: From January 1991 through May 2003, 427 eligible patients with International Federation of Gynecology and Obstetrics (FIGO) stage IIIB-C and IV epithelial ovarian carcinoma were randomly assigned to undergo systematic pelvic and para-aortic lymphadenectomy (n = 216) or resection of bulky nodes only (n = 211). Progression-free survival and overall survival were analyzed using a log-rank statistic and a Cox multivariable regression analysis. All statistical tests were two-sided. Results: After a median follow-up of 68.4 months, 292 events (i.e., recurrences or deaths) were observed, and 202 patients had died. Sites of first recurrences were similar in both arms. The adjusted risk for first event was statistically significantly lower in the systematic lymphadenectomy arm (hazard ratio [HR] = .75, 95% confidence interval [CI] = 0.59 to 0.94; P = .01) than in the no-lymphadenectomy arm, corresponding to 5-year progression-free survival rates of 31.2 and 21.6% in the systematic lymphadenectomy and control arms, respectively (difference = 9.6%, 95% CI = 1.5% to 21.6%), and to median progression-free survival of 29.4 and 22.4 months, respectively (difference = 7 months, 95% CI = 1.0 to 14.4 months). The risk of death was similar in both arms (HR = 0.97, 95% CI = 0.74 to 1.29; P = .85), corresponding to 5-year overall survival rates of 48.5 and 47%, respectively (difference = 1.5%, 95% CI = −8.4% to 10.6%), and to median overall survival of 58.7 and 56.3 months, respectively (difference = 2.4 months, 95% CI = −11.8 to 21.0 months). Median operating time was longer, and the percentage of patients requiring blood transfusions was higher in the systematic lymphadenectomy arm than in the no-lymphadenectomy arm (300 versus 210 minutes, P <.001, and 72% versus 59%; P = .006, respectively). Conclusion: Systematic lymphadenectomy improves progression-free but not overall survival in women with optimally debulked advanced ovarian carcinoma.

29 August 2006 in British Journal of Cancer
Verified
Journal Article
Open access
AMA Maggioni
A Maggioni
PPP Benedetti Panici
P Benedetti Panici
TDT Dell'ANna
T Dell'ANna
FLFabio Landoni
Fabio Landoni
ALA Lissoni
A Lissoni
CMC Mangioni
C Mangioni
No randomised trials have addressed the value of systematic aortic and pelvic lymphadenectomy (SL) in ovarian cancer macroscopically confined to the pelvis. This study was conducted to investigate the role of SL compared with lymph nodes sampling (CONTROL) in the management of early stage ovarian cancer. A total of 268 eligible patients with macroscopically intrapelvic ovarian carcinoma were randomised to SL (N=138) or CONTROL (N=130). The primary objective was to compare the proportion of patients with retroperitoneal nodal involvement between the two groups. Median operating time was longer and more patients required blood transfusions in the SL arm than the CONTROL arm (240 vs 150 min, P<0.001, and 36 vs 22%, P=0.012, respectively). More patients in the SL group had positive nodes at histologic examination than patients on CONTROL (9 vs 22%, P=0.007). Postoperative chemotherapy was delivered in 66% and 51% of patients with negative nodes on CONTROL and SL, respectively (P=0.03). At a median follow-up of 87.8 months, the adjusted risks for progression (hazard ratio [HR] =0.72, 95%CI=0.46–1.21, P=0.16) and death (HR=0.85, 95%CI=0.49–1.47, P=0.56) were lower, but not statistically significant, in the SL than the CONTROL arm. Five-year progression-free survival was 71.3 and 78.3% (difference=7.0%, 95% CI=–3.4–14.3%) and 5-year overall survival was 81.3 and 84.2% (difference=2.9%, 95% CI=−7.0–9.2%) respectively for CONTROL and SL. SL detects a higher proportion of patients with metastatic lymph nodes. This trial may have lacked power to exclude clinically important effects of SL on progression free and overall survival.

1 December 2003 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
MZMarzio Angelo Zullo
Marzio Angelo Zullo
NMNatalina Manci
Natalina Manci
RARoberto Angioli
Roberto Angioli
LMLudovico Muzii
Ludovico Muzii
PPPierluigi Benedetti Panici
Pierluigi Benedetti Panici

1 May 2000 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
RARoberto Angioli
Roberto Angioli
OGOrlando Gómez-Marín
Orlando Gómez-Marín
GCGuilherme Cantuaria
Guilherme Cantuaria
MOMary J. O’sullivan
Mary J. O’sullivan

1 December 2003 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
RARoberto Angioli
Roberto Angioli
MPManuel Penalver
Manuel Penalver
LMLudovico Muzii
Ludovico Muzii
LMLuis Mendez
Luis Mendez
RMRamin Mirhashemi
Ramin Mirhashemi
PPPierluigi Benedetti Panici
Pierluigi Benedetti Panici